Literature DB >> 11325818

Erythropoietin and erythropoietin receptor expression in human cancer.

G Acs1, P Acs, S M Beckwith, R L Pitts, E Clements, K Wong, A Verma.   

Abstract

Erythropoietin (EPO) stimulates the growth of erythroblasts in the bone marrow (C. Lacombe and P. Mayeux, NEPHROL: DIAL: TRANSPLANT:, 14 (SUPPL: 2): 22-28, 1999). We report basal and hypoxia-stimulated expression of EPO and its receptor, EPOR, in human breast cancer cells, and we demonstrate EPO-stimulated tyrosine phosphorylation and the proliferation of these cells in vitro. In 50 clinical specimens of breast carcinoma, we report high levels of EPO and EPOR associated with malignant cells and tumor vasculature but not with normal breast, benign papilloma, or fibrocystic tissue. Hypoxic tumor regions display the highest levels of EPO and EPOR expression. Enhanced EPO signaling may contribute to the promotion of human cancer by tissue hypoxia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325818

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  78 in total

1.  Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.

Authors:  Yoshihiko Ikeda; Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Souheil El-Chemaly; Bernadette R Gochuico; Rose M May; Olanda M Hathaway; Shaowei Li; Ji-an Wang; Thomas N Darling; Mario Stylianou; Joel Moss
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-29       Impact factor: 5.464

2.  Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

Authors:  Ahmed Mohyeldin; Huasheng Lu; Clifton Dalgard; Stephen Y Lai; Noam Cohen; Geza Acs; Ajay Verma
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  Phosphorylation of Bcl-associated death protein (Bad) by erythropoietin-activated c-Jun N-terminal protein kinase 1 contributes to survival of erythropoietin-dependent cells.

Authors:  Hongbin Deng; Jingpu Zhang; Taewon Yoon; Danqing Song; Diandong Li; Anning Lin
Journal:  Int J Biochem Cell Biol       Date:  2010-11-21       Impact factor: 5.085

4.  Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer.

Authors:  Charles L Bennett; Pamela S Becker; Eric H Kraut; Athena T Samaras; Dennis P West
Journal:  Semin Dial       Date:  2008-12-05       Impact factor: 3.455

5.  Functional erythropoietin autocrine loop in melanoma.

Authors:  Suresh M Kumar; Geza Acs; Dong Fang; Meenhard Herlyn; David E Elder; Xiaowei Xu
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

6.  Expression and functional significance of the erythropoietin receptor in hepatocellular carcinoma.

Authors:  Milljae Shin; Doopyo Hong; Zhengyun Zhang; You Min Kim; Wookjong Lee; Jae-Won Joh; Sung-Joo Kim
Journal:  HPB (Oxford)       Date:  2013-03-15       Impact factor: 3.647

Review 7.  Stimulating erythropoiesis in inflammatory bowel disease associated anemia.

Authors:  Georgia Tsiolakidou; Ioannis-E Koutroubakis
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

8.  Erythropoietin receptor (EpoR) agonism is used to treat a wide range of disease.

Authors:  Fabian Sanchis-Gomar; Carme Perez-Quilis; Giuseppe Lippi
Journal:  Mol Med       Date:  2013-04-30       Impact factor: 6.354

9.  Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events.

Authors:  M Aapro; B Osterwalder; A Scherhag; H U Burger
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.